44 results about "Desmopressin" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

The present invention relates to a novel method for the preparation of a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, comprising providing a desmopressin containing granulate suitable for compression to a pharmaceutically acceptable tablet, as well as to solid dosage forms, preferably tablets, obtainable by said method.

The present invention relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, and to say solid dosage form. In one embodiment it specifically relates to a blister pack for pharmaceutical use comprising blisters containing a solid dosage form of desmopressin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent and/or carrier, wherein said solid dosage form is adapted to prevent moisture related degradation of said desmopressin.

A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

The invention relates to a method for solid cyclizing synthesis of desmopressin. The method solves the technical problem that the existing air liquid-phase oxidation method produces a large amount of waste liquid, utilizes behindhand processes, has low efficiency and produces more by-products because of oxidation adopting iodine as an oxidizing agent. The method comprises the following steps of orderly coupling nine amino acids to a RinkAmideAm resin, wherein the coupled amino acids orderly comprise Fmoc-Gly-OH, Fmoc-D-Arg(pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH and Mpa(Trt)-OH, removing protective groups Trt on Cys(Trt) and Mpa(Trt) by TFA/DCM having content of 1%, carrying out solid cyclizing synthesis by an oxidation reagent to obtain a cyclopeptide resin and carrying out cracking to obtain desmopressin. The invention provides the method for solid cyclizing synthesis of desmopressin and the method has simple processes, a low cost and a high yield and is suitable for large-scale production.

The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.

The invention provides a synthesis method of desmopressin. The method comprises the following steps: coupling amino acid monomers and Mpa onto a solid carrier, from which the protective groups have been moved, in a water solution according to a sequence of PG-Gly-OH, PG-D-Arg-OH, PG-Pro-OH, PG-Cys(Trt)-OH, PG-Asn-OH, PG-Gln-OH, PG-Phe-OH, PG-Tyr-OH, and Mpa, wherein the PG represents a water-soluble amino protective group, oxidizing, cracking, and purifying. The provided synthesis method does not use any organic solvent, the cost is saved, the environment is protected, moreover, part of the side-chain functional groups in the peptide sequence does not need to be protected, the operation is simple, the cost is low, the yield is high, and thus the provided synthesis method can generate considerable economic benefits, is very practical, and has a wide application prospect.

The present disclosure relates generally to pharmaceutical compositions comprising an active ingredient and a stabilizing agent, wherein the active ingredient is desmopressin or a pharmaceutically acceptable salt thereof, and wherein the stabilizing agent is one or more gums. The present disclosure further relates to methods of increasing the stability of a pharmaceutical composition comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient; methods for preparing orally disintegrating films comprising desmopressin or a pharmaceutically acceptable salt thereof and orally disintegrating films prepared thereby; and methods of treating or preventing nocturnal enuresis or nocturnal polyuria by administering stabilized pharmaceutical compositions comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient.

The invention discloses a synthetic method of desmopressin. The synthetic method comprises the following steps: 1) selecting solid phase carrier resin; 2) synthesizing main chain peptide resin; 3) conducting cracking to remove resin and protective groups; and 4) conducting liquid phase electrochemical oxidation and coupling disulfide bonds to obtain the desmopressin. According to the method, the problem of specific selectivity of reaction can be avoided, the utilization rate of fragment peptide resin, the utilization rate of main chain fragments and the atom utilization rate can be increased,so that the production cost is reduced, the use of chemical oxidants iodine and hydrogen peroxide is avoided, and the method is more environment-friendly and more conforms to the concept of green chemistry.